Last reviewed · How we verify
Sr-89
Strontium-89 is a beta-emitting radioisotope that localizes to areas of increased bone metabolism and delivers targeted radiation to relieve bone pain in patients with skeletal metastases.
Strontium-89 is a beta-emitting radioisotope that localizes to areas of increased bone metabolism and delivers targeted radiation to relieve bone pain in patients with skeletal metastases. Used for Bone pain palliation in patients with skeletal metastases from cancer (prostate cancer, breast cancer, and other malignancies with bone involvement).
At a glance
| Generic name | Sr-89 |
|---|---|
| Also known as | strontium-89 chloride |
| Sponsor | Peking Union Medical College Hospital |
| Drug class | Radiopharmaceutical; beta-emitting radioisotope |
| Target | Bone hydroxyapatite (calcium analog); osteoblasts in areas of increased bone metabolism |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Mechanism of action
Sr-89 is taken up by osteoblasts in bone lesions due to its chemical similarity to calcium. Once localized to sites of increased bone turnover (such as metastatic lesions), it emits beta particles that deliver high local radiation dose to the tumor and surrounding bone tissue, causing pain relief. The mechanism provides palliative benefit by destroying metastatic bone lesions and reducing osteoclastic activity.
Approved indications
- Bone pain palliation in patients with skeletal metastases from cancer (prostate cancer, breast cancer, and other malignancies with bone involvement)
Common side effects
- Bone marrow suppression (thrombocytopenia, leukopenia)
- Transient increase in bone pain (flare reaction)
- Nausea
Key clinical trials
- TriCalm Hydrogel® in the Treatment of Immunotherapy-Related Pruritus (PHASE2)
- Successful Pregnancy and Delivery After AOA (NA)
- Zoledronate, Vitamin D, and Calcium With or Without Strontium 89 or Samarium 153 in Preventing or Delaying Bone Problems in Patients With Bone Metastases From Prostate Cancer, Lung Cancer, or Breast Cancer (PHASE3)
- Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases (PHASE4)
- The Strontium Chloride Associated With Photobiomodulation in the Control of Post-bleaching Sensitivity (NA)
- Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases (PHASE2)
- Novel Approach With Double Agent Artificial Oocyte Activation for Repeated Fertilization Failure Due to Combined Sperm and Oocyte Factor (NA)
- Artificial Oocyte Activation Comparing Tow Different Agents (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sr-89 CI brief — competitive landscape report
- Sr-89 updates RSS · CI watch RSS
- Peking Union Medical College Hospital portfolio CI